This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/5/2026
Good morning and welcome to the Intensity Therapeutics third quarter 2026 financial results conference call. Joining the call today is Lewis H. Bender, Intensity's president and CEO, and Joseph Talamo, Intensity's chief financial officer. Shortly before this call, Intensity issued a press release announcing its third quarter 2026 financial results, which is available under the news and events section of the company website. Shortly after this webcast, a replay of this call will also be posted. Before we begin, The company reminds you that comments made by management during this conference call contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Intensity Therapeutics. These statements include, but are not limited to, statements relating to the company's expected future plans, cash runway, development activities, projected milestones, business activities or results. Forward-looking statements are based on current expectations and assumptions are subject to risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties is included in the company's earnings release issued today. For a more complete list and description of risk factors, I encourage you to review the company's filings with the Securities and Exchange Commission, including without limitation its forms 10-K, 10-Q, and 8-Ks. Furthermore, the content of this conference call contains time-sensitive information. Thank you, Wyatt, and thank you everyone for joining us this morning. It is my pleasure to provide the latest update of our company's progress in the Invincible 3 and Invincible 4 studies.
our publications and presentation strategy, our business development activities, and our plans for the rest of 26 and 27. But first, I will turn the call over to Joe Talamo, our CFO, to discuss our third quarter financial results. Joe?
Thanks, Lou, and good morning. I'm pleased to join you today and to present a summary of our third quarter 2026 financial results. Our research and development expenses were $2.4 million for the third quarter of 2026, compared with $1.6 million for the same prior year period, reflecting an increase of $876,456. Clinical trial expenses for our Phase III Invincible III study were $1.5 million during the third quarter of 2026. compared with $1 million for the same prior year period. In the current year order, we resumed new patient enrollment activities in the Invincible 3 study in a limited number of U.S. sites after pausing new site activations and patient enrollment in March 2025 due to funding constraints. During this pause, we continued to treat and monitor patients previously enrolled in the study in cooperation with our CROs. We have prioritized commencing full patient enrollment and site activations once sufficient incremental funding is obtained. Our clinical trial expenses also included $104,000 for our Phase 2 Invincible 4 study, which also resumed patient enrollment and treatment in the third quarter of 2026. We expect the Invincible 4 study costs to increase in the coming quarters as we target completing enrollment in this study by the end of 2027. Blue will provide an operational update on both studies shortly. During the third quarter of 2026, we also initiated a new manufacturing batch of INT 230-6, incurring $162,000 in higher manufacturing costs. We expect this batch will be completed in the first quarter of 2027 and will likely be sufficient to fully supply both ongoing clinical studies. Lastly, research and development employee compensation related expenses were $184,000 higher during the current quarter due to an estimated bonus accrual in the current year period compared to no bonus accrual in the prior year period. Turning now to G&A, general and administrative expenses were $1.3 million for the third quarter of 2026 and were unchanged compared with the same prior year period. Within G&A, minor increases in employee compensation-related expenses and consulting expenses were offset by minor decreases in insurance costs during the third quarter of 2026 compared to the same period same prior year period. Overall, net loss was $3.5 million for the third quarter of 2026 compared with a $2.7 million loss for the third quarter of 2025 representing an increase in net loss of $873,000 or 33%. Our cash burn from operating activities for the nine months ended September 30 was $6.7 million, reflecting an average monthly operating activities cash burn of $741,000 over the first nine months of 2026. We estimate that our operating cash burn will average approximately $1 million per month in the final quarter of 2026 as we continue to advance our clinical studies and manufacture the new INT230-6 Batch. Turning now to our balance sheet, as of September 30, 2026, we had cash and cash equivalents of $8.5 million. During the third quarter of 2026, we raised $1.5 million in net proceeds from the issuance of common stock under our at-the-market facility. And for the nine months ended September 30, 2026, we raised $3.2 million in net proceeds under the at-the-market facility. We expect to continue to use this facility opportunistically to raise capital, and we'll continue to explore other sources of dilutive and non-dilutive capital as we seek to scale up our clinical activities moving forward. With that, I'll now turn the call back to Lou for a discussion on our clinical programs and business development activities. Lou? Thank you, Joe.
You're reading a preview of the INTS Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing